Figure 4.

Antitumour properties of LBH589 and PI3K/mTOR/AKT inhibitors in a xenotransplant model of HNSCC. (A–C) Six week old NOD/SCID mice (groups of four) were injected with 2.5 × 10⁵ Cal27 cells on day 0. 28 days after injection of cells mice were treated with (i) vehicle only, (ii) LBH589 (30 mg kg ⁻¹day⁻¹ i.p.), (iii) BEZ235 (30 mg kg ⁻¹day⁻¹ p.o.), (iv) BGT226 (10 mg kg ⁻¹day⁻¹ p.o.), (v) BKM120 (7.5 mg kg ⁻¹day⁻¹ p.o), (vi) LBH589 (30 mg kg ⁻¹day⁻¹ i.p.)+BEZ235 (30 mg kg ⁻¹day⁻¹ p.o.), (vii) LBH589 (30 mg kg ⁻¹day⁻¹ i.p.)+BGT226 (10 mg kg ⁻¹day⁻¹ p.o.), (viii) LBH589 (30 mg kg ⁻¹day⁻¹ i.p.)+BKM120 (7.5 mg kg ⁻¹day⁻¹ p.o.). Tumour volume was measured over a period of 60 days post-tumour inoculation or until a volume of 1 cm³ was reached. Data presented as mean±s.e.m. of individual measurements from four mice per group. Dotted line indicates beginning of treatment for distinct groups.